Drug-induced peripheral neuropathy can begin weeks to months after initiation of treatment with a particular drug and reach a peak at, or after, the end of treatment. In most cases, the pain and paresthesia completely resolve after cessation of treatment. However, in some cases, it is only partially reversible and can be permanent.

We carried out this study to evaluate the incidence of neurologic problems like peripheral neuropathy in patients on long-term medication with amiodarone by nerve conduction studies.

**MATERIALS AND METHODS**

We carried a retrospective study on 27 patients who were given long-term amiodarone therapy and compared with 15 controls without neurological problem. After obtaining the Institutional Ethical Committee clearance, the study was done at Prathima Institute of Medical Sciences, Karimnagar, Telangana, from January 1, 2015, to December 31, 2017, using hospital medical records. We limited the primary analysis to the amiodarone-treated patients who were seen in the

**ABSTRACT**

**Background:** Amiodarone is an iodine-rich drug that is a highly effective and widely used as an antiarrhythmic agent for the treatment of symptomatic supraventricular and ventricular tachyarrhythmias. Amiodarone is associated with many adverse effects that involve different organs. Incidence of neurologic problems like peripheral neuropathy has been reported after long-term usage of amiodarone.

**Aim of the Study:** The aim of the present study is to evaluate the incidence of neurologic problems like peripheral neuropathy in patients on long-term medication with amiodarone.

**Materials and Methods:** We carried a retrospective medical record analysis of cardiac patients treated with amiodarone at Prathima Institute of Medical Sciences, Karimnagar, Telangana, from January 1, 2015 to December 31, 2017. 27 patients on long-term amiodarone therapy with neurologic problems were compared with 15 controls without neurological disease. Patients on whom nerve conduction studies and electromyography were performed after admission were selected. All possible neurologic adverse effects that might be attributable to amiodarone were recorded and tabulated.

**Results:** Neurologic problems included tremor, gait ataxia, peripheral neuropathy, and cognitive impairment. The primary risk factor for amiodarone neurotoxic effects was duration of treatment, not age, drug dose, sex, or indication for therapy.

**Conclusion:** Amiodarone infrequently causes clinically significant neurologic toxic effects. Substantially higher estimates of neurotoxic effects in the early studies may be related to a much higher daily dose during those times.

**Key words:** Amiodarone, arrhythmia, cognitive impairment, naranjo algorithm, peripheral neuropathy

**INTRODUCTION**

Amiodarone is a diodinated benzofuran derivative initially developed in the 1960s as an antianginal agent. It was later used as a cardiac antiarrhythmic agent in the management of supraventricular and ventricular arrhythmias. It belongs to Class III antiarrhythmic agents. Its antiarrhythmic effect is by virtue of prolonging action potential duration in contrast to drugs that act by local anesthesia properties. Amiodarone has properties of all four groups, i.e., it blocks fast sodium channel (Class I), adrenergic receptors (Class II): IK channels (Class III), and “L” calcium channel (Class IV).

Amiodarone was first synthesized by Labaz laboratories in Belgium as an antianginal agent during a systemic search for potent coronary vasodilators. Common adverse drug effects include hepatotoxicity, corneal microdeposits, and thyroid dysfunction, and the drug was initially reported to have a strong association to neurotoxicity including reversible peripheral neuropathy. Muscle weakness and peripheral neuropathy have also been reported in 10% of the patients who were administered the antiarrhythmic agent amiodarone.

Drug-induced peripheral neuropathy can begin weeks to months after initiation of treatment with a particular drug and reach a peak at, or after, the end of treatment. In most cases, the pain and paresthesia completely resolve after cessation of treatment. However, in some cases, it is only partially reversible and can be permanent.

We carried out this study to evaluate the incidence of neurologic problems like peripheral neuropathy in patients on long-term medication with amiodarone by nerve conduction study.

**MATERIALS AND METHODS**

We carried a retrospective study on 27 patients who were given long-term amiodarone therapy and compared with 15 controls without neurological problem. After obtaining the Institutional Ethical Committee clearance, the study was done at Prathima Institute of Medical Sciences, Karimnagar, Telangana, from January 1, 2015, to December 31, 2017, using hospital medical records. We limited the primary analysis to the amiodarone-treated patients who were seen in the
neurologic clinic (for any reason) after long-term amiodarone therapy was initiated.

We compared the clinical characteristics of the patients with amiodarone neurotoxic effects with all patients prescribed amiodarone over the period of the study who did not develop neurologic problems[12] for sex, treatment indication, age, treatment duration, and dose. Nerve conduction studies and electromyography findings were noted. Records were reviewed for neurologic problems developing after initiation of long-term amiodarone therapy. Diabetes mellitus, Liver diseases, Uremia, Thyroid disorders, Collagen vascular disorders, Paraproteinemias, Imipramine, Amitriptylin, Hydralazine.

**RESULTS**

We recognized 40 amiodarone-treated patients referred to neurodepartment for neurologic adverse events. After reviewing their records, 10 patients were excluded because the neurologic problem developed before the initiation of amiodarone therapy and 3 were excluded because the problem was not neurologic. Among 27 remaining patients, 9 had problems considered to be biologically unlikely as drug effects (5 strokes, 1 meningioma, 1 subdural hematoma, 1 carpal tunnel syndrome, and 1 transient ischemic attack secondary to a documented carotid dissection). The problems of other three patients were considered as possible adverse effects but with other likelier causes (asymmetric AQ2 neuropathy in the setting of systemic vasculitis in two patients and peripheral neuropathy in the setting of carboplatin and paclitaxel therapy in the other patient).

The remaining 15 patients problem was judged to be biologically plausible and likely drug effects: New-onset tremor (6 patients), worsening of preexisting essential tremor,[3] peripheral neuropathy,[3] tremor with gait ataxia,[6] gait ataxia plus mild peripheral neuropathy,[1] and cognitive impairment.[11] In three cases, these clinical problems were noticed incidentally by neurologists when assessing the patients for other problems. Of these 15 patients (11 male and 4 female), 13 were prescribed amiodarone for atrial arrhythmias and 2 for ventricular arrhythmias.

The mean age of the affected patients at the time they were seen in neurology was 73.13 years (range, 65–82 years) and the mean age when starting amiodarone therapy was 70.1 years (range, 63–80 years), the mean daily dose of amiodarone hydrochloride was 220 mg (range, 100–400 mg), and the average length of time receiving treatment was 30.6 months (range, 2–62 months). In nine cases, administration of the drug was stopped or reduced, and of these, all but two patients improved. Naranjo Adverse Drug Reaction probability algorithm estimates the likely causality of an adverse drug reaction. We followed the algorithm and found that out of 15 biologically plausible drug effects, 9 were categorized as probable and 6 as possible and none were considered either definite or doubtful [Table 1].

---

**Table 1: The clinical characteristics of the study sample**

| Case No. | Age | Sex | Duration of amiodarone treatment in months | Dose in Mg | Indication | Neurologic problem | Neurologic problem stopped or reduced treatment | Outcome criteria for ADR |
|----------|-----|-----|------------------------------------------|------------|------------|-------------------|-----------------------------------------------|------------------------|
| 1        | 73  | M   | 14                                       | 200        | AF         | Tremor            | Stopped                                       | Clinically improved    |
| 2        | 68  | M   | 38                                       | 200        | AF         | Worsening of preexisting essential tremor      | No                             | NA                      |
| 3        | 74  | F   | 38                                       | 100        | AF         | Peripheral neuropathy                         | Stopped                        | Probable               |
| 4        | 72  | M   | 2                                        | 200        | AF         | Worsening of preexisting essential tremor      | Stopped                        | Probable               |
| 5        | 68  | M   | 29                                       | 200        | VT         | Tremor                                        | Reduced to 100 mg              | Clinically improved    |
| 6        | 73  | M   | 24                                       | 200        | AF         | Peripheral neuropathy                         | No                             | Possible               |
| 7        | 65  | M   | 21                                       | 400        | AF         | Tremor with gait ataxia                       | Reduced to 100 mg              | Clinically improved    |
| 8        | 76  | M   | 36                                       | 200        | AF         | Tremor                                        | Clinically improved           | Clinically improved    |
| 9        | 67  | F   | 62                                       | 200        | VT         | Peripheral neuropathy                         | Stopped                        | Clinically improved    |
| 10       | 82  | M   | 22                                       | 400        | AF         | Worsening of preexisting essential tremor      | Reduced to 100 mg              | Clinically improved    |
| 11       | 75  | M   | 39                                       | 200        | AF         | Tremor                                        | No                             | NA                     |
| 12       | 76  | F   | 21                                       | 200        | AF         | Gait ataxia plus mild peripheral neuropathy   | Stopped                        | Probable               |
| 13       | 73  | M   | 37                                       | 200        | AF         | Tremor                                        | No                             | Clinically improved    |
| 14       | 81  | M   | 44                                       | 200        | AF         | Cognitive impairment                          | Stopped                        | Probable               |
| 15       | 74  | F   | 32                                       | 200        | AF         | Tremor                                        | No                             | Clinically improved    |

ADR: Adverse drug reaction, AF: Atrial fibrillation, NA: Non-applicable, ND: Not determined, VT: Ventricular tachyarrhythmia
We compared these patients with 15 adults who received amiodarone therapy during our study period and did not have any neurotoxic effects [Table 2]. The mean age, sex, type of arrhythmia, and mean daily dose were almost similar. However, those with neurotoxic effects took amiodarone for significantly longer (mean, 30.6 months vs. 16.8 months).

**DISCUSSION**

Amiodarone hydrochloride is a Class III antiarrhythmic drug prescribed commonly for atrial fibrillation and ventricular arrhythmias. The initial experience with this drug suggested substantial potential for neurologic toxic effects, with frequencies in the early reports ranging from 27.5% to as high as 74%, the most common of these neurologic adverse effects have been tremor, ataxia, and peripheral neuropathy. On the other hand, the frequency of neurologic adverse effects in longer term amiodarone clinical trials has been much lower, at <5%. It is noted that the incidence of neurological symptoms is directly related to a significant reduction in maintenance doses of amiodarone from 600 mg to 200 mg, while the highest risk factor for adverse drug effects apart from increased dose appears to be the length of drug therapy. As a result of advances in surgical procedures, the use of amiodarone has declined over the years.

The main risk factor for amiodarone neurotoxic effects in our study was length of time receiving therapy. This is in agreement with previous studies of Vorperian et al. and Orr and Ahlskog.

Age was not a risk factor in our study, in agreement with a previous report, and neither was sex or indication for amiodarone therapy. With the amiodarone dosing strategy of the current era, the risk of neurologic toxic effects is small; however, it may be suspected among patients with otherwise unexplained tremor, gait ataxia, peripheral neuropathy, or cognitive impairment. Hence, patients who are on long-term amiodarone therapy should be monitored for any neurotoxic effects.

**Future Research**

Early detection and subsequent modification of the treatment regimen is one of the most important factors for reducing the incidence and severity of drug-induced peripheral neuropathy. Better understanding of the underlying pathophysiology of this side effect will be a cornerstone for further improvement of both prevention and treatment of the neuropathy. There is also a need for further randomized, controlled trials to clarify the efficacy of possible neuroprotective agents.

**CONCLUSION**

Patients with amiodarone-induced polyneuropathy were older and receiving higher mean daily maintenance dose of amiodarone. Electrophysiological studies detected subclinical polyneuropathy which helped in closely following these patients to detect clinical symptoms and signs of neuropathy. Prospective studies on a larger sample are needed to determine the incidence of neurotoxicity with amiodarone use and its correlation with histopathological studies will help in determining the mechanism of neuropathy and to compare and draw definite conclusions.

**REFERENCES**

1. Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: Three cases and a review of the literature. J Clin Neuromusc Dis 2002;3:97-105.
2. Clem JR, Farver DK, Fischer JR, Johnson TJ. Dronedarone: A safety comparison to amiodarone. Curr Drug Saf 2010:5:251-6.
3. Roden DM. Antiarrhythmic drugs. In: Goodman LS, Gilman A, editors. The Pharmacologic Basis of Therapeutics. 9th ed. New York: Pergamon; 1996. p. 858-62.
4. Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66:865-9.
5. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975-83.
6. Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984;34:669-71.
7. Flanagan EP, Harper CM, St Louis EK, Silber MH, Josephs KA. Amiodarone-associated neuromyopathy: A report of four cases. Eur J Neurol 2012;19:e50-1.
8. Kang HM, Kang YS, Kim SH, Seong JK, Kang DY, Lee HY, et al. Amiodarone-induced hepatitis and polyneuropathy. Korean J Intern Med 2007;22:225-9.
9. Podrid PJ. Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995;122:689-700.
10. Pellissier JF, Pouget J, Cros D, De Victor B, Serratrice G, Toga M. Peripheral neuropathy induced by amiodarone chlo- rohydrate. J Neurol Sci 1984;63:251-66.
11. Fraser AG, McQueen IN, Watt AH, Stephens MR. Peripheral neuropathy during longterm high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry 1985;48:576-8.
12. Windelbank AJ, Grisold W. Chemotherapy-induced neuromyopathy. J Peripher Nerv Syst 2008;13:27-46.
13. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hilleghe HL, et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: A randomized trial. JAMA 2008;300:1784-92.
14. Naranjo CA, Busto U, Serrador EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
15. Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med 1987;147:881-4.
16. Cairns JA, Connolly SJ, Roberts R, Gent M. Canadian amiodarone myocardial infarction arrhythmia trial

| Table 2. Comparison of patients with amiodarone neurotoxic effects and controls without effects |
|-----------------------------------------------|--------|--------|
| **Character**                | **Study sample** | **Controls** |
| Mean age in years            | 73-13  | 71-93  |
| Gender                       |        |        |
| Male                         | 11     | 12     |
| Female                       | 4      | 3      |
| Indication                   |        |        |
| AF                           | 13     | 12     |
| VF                           | 2      | 3      |
| Mean dose in mg              | 220    | 200    |
| Mean duration in months      | 30.6   | 16.8   |

AF: Atrial fibrillation, VT: Ventricular tachyarrhythmia
investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.

17. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997;30:791-8.

How to cite this Article: Kylasam P, Kumar PR, Israel J, Anish P. Evaluation of frequency, characteristics, and risk factors of neurotoxicity in patients on long-term amiodarone by nerve conduction studies. Asian Pac. J. Health Sci., 2018; 5(1):162-165.

Source of Support: Nil, Conflict of Interest: None declared.